サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1720945

セルベースアッセイの世界市場：オファリング別、技術別、用途別、エンドユーザー別、地域別 - 2030年までの予測

Cell Based Assays Market by Offering (Consumables, Instruments & Software), Technology, Application (Drug Discovery ) - Global Forecast to 2030

出版日
ページ情報
英文 449 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.89円
セルベースアッセイの世界市場：オファリング別、技術別、用途別、エンドユーザー別、地域別 - 2030年までの予測
出版日: 2025年04月21日
発行: MarketsandMarkets
ページ情報: 英文 449 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

セルベースアッセイの市場規模は、2025年の178億4,000万米ドルから2030年には275億5,000万米ドルに達すると予測され、2025年から2030年の予測期間中のCAGRは9.1%になるとみられています。

この成長は、創薬需要の増加とこの分野におけるセルベースアッセイのニーズの高まりによるところが大きいです。さらに、製薬業界やバイオテクノロジー業界からの研究開発投資の増加が、セルベースアッセイ市場の成長を促進しています。さらに、がんの罹患率の上昇が先進的な治療法に対する需要を高めており、これが市場拡大をさらに後押ししています。また、慢性疾患や個別化医療におけるセルベースアッセイの用途拡大も、今後数年間の市場成長を促進すると期待されています。

調査範囲
調査対象年 2024年～2030年
基準年 2024年
予測期間 2024年～2030年
検討単位 金額（10億米ドル）
セグメント オファリング別、技術別、用途別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

セルベースアッセイ市場は用途別に創薬、基礎研究、遺伝子研究、その他に区分されます。創薬セグメントはさらに毒性試験、薬物動態試験、薬力学試験に分類されます。2024年、創薬セグメントは世界のセルベースアッセイ市場で最大のシェアを占めました。がんの有病率の上昇が先進的な治療法への需要を牽引しており、これがセルベースアッセイ市場におけるこのセグメントの成長を促進しています。さらに、研究開発への投資の増加、新薬の導入、製薬会社やバイオテクノロジー企業に創薬サービスを提供する受託研究機関の増加も、セルベースアッセイ市場における同分野の継続的成長に寄与すると期待されています。

セルベースアッセイ市場は、技術別にフローサイトメトリー、ハイスループットスクリーニング、ラベルフリー検出、その他の技術に分類されます。2024年、フローサイトメトリーはこのカテゴリーの中で世界のセルベースアッセイ市場で最大のシェアを占めています。フローサイトメトリー分野の成長は、主に細胞ベースのアッセイで広く使用され、複数の測定が可能になったことによるものです。さらに、細胞分析および特性解析のための先端技術の採用が増加していることから、セルベースアッセイ市場におけるこのセグメントの成長はさらに高まると予想されます。

セルベースアッセイ市場は大きく6つの地域：北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに分けられます。2024年、北米のセルベースアッセイ市場は米国が独占しています。世界最大のバイオ医薬品市場として、米国はバイオ医薬品の研究と投資をリードしています。また、同国はライフサイエンス分野の研究開発を支える強固なヘルスケアインフラを誇っています。

さらに、数多くのバイオ医薬品企業が存在し、バイオテクノロジー産業における研究活動が活発化していることも、米国の市場成長を後押ししています。さらに、がん罹患率の上昇に伴い、先進的な細胞ベースの治療法の開発が重視されるようになっていることも、セルベースアッセイ市場の成長に寄与しています。

当レポートでは、世界のセルベースアッセイ市場について調査し、オファリング別、技術別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 技術分析
  • バリューチェーン分析
  • 価格分析
  • エコシステム分析
  • 顧客ビジネスに影響を与える動向/混乱
  • 特許分析
  • 2025年～2026年の主な会議とイベント
  • 関税と規制状況
  • ポーターのファイブフォース分析
  • 主要な利害関係者と購入基準
  • 投資と資金調達のシナリオ
  • 貿易分析
  • AI/生成AIがセルベースアッセイ市場に与える影響
  • 2025年の米国関税がセルベースアッセイ市場に与える影響

第6章 セルベースアッセイ市場（オファリング別）

  • イントロダクション
  • 消耗品
  • 機器
  • サービス
  • ソフトウェア

第7章 セルベースアッセイ市場（技術別）

  • イントロダクション
  • フローサイトメトリー
  • ハイスループットスクリーニング
  • ラベルフリー検出
  • その他

第8章 セルベースアッセイ市場（用途別）

  • イントロダクション
  • 創薬
  • 基礎研究
  • 遺伝学研究
  • その他

第9章 セルベースアッセイ市場（エンドユーザー別）

  • イントロダクション
  • 製薬・バイオテクノロジー企業
  • CRO
  • 学術研究機関

第10章 セルベースアッセイ市場（地域別）

  • イントロダクション
  • 北米
    • マクロ経済見通し
    • 米国
    • カナダ
  • 欧州
    • マクロ経済見通し
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • マクロ経済見通し
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ
    • マクロ経済見通し
    • ブラジル
    • メキシコ
    • その他
  • 中東
    • マクロ経済見通し
    • GCC諸国
    • その他
  • アフリカ
    • 市場の成長を支える効果的な診断の必要性の高まり
    • マクロ経済見通し

第11章 競合情勢

  • 概要
  • 主要参入企業の戦略/強み、2021年～2025年
  • 収益分析、2020年～2024年
  • 市場シェア分析、2024年
  • 企業評価マトリックス：主要参入企業、2024年
  • 企業評価マトリックス：スタートアップ/中小企業、2024年
  • 企業評価と財務指標
  • ブランド/製品比較
  • 競合シナリオ

第12章 企業プロファイル

  • イントロダクション
  • 主要参入企業
    • DANAHER
    • THERMO FISHER SCIENTIFIC INC.
    • MERCK KGAA
    • BD
    • AGILENT TECHNOLOGIES, INC.
    • LONZA
    • EUROFINS SCIENTIFIC
    • CHARLES RIVER LABORATORIES
    • BIO-RAD LABORATORIES, INC.
    • REVVITY
    • SARTORIUS AG
    • CORNING INCORPORATED
    • PROMEGA CORPORATION
    • CELL SIGNALING TECHNOLOGY, INC.
    • ENZO BIOCHEM INC.
    • CARNA BIOSCIENCES, INC.
    • INTERTEK GROUP PLC
    • BICO
  • その他の企業
    • CELL BIOLABS, INC.
    • REACTION BIOLOGY
    • AAT BIOQUEST, INC.
    • PESTKA BIOMEDICAL LABORATORIES, INC.
    • NEUROMICS
    • BPS BIOSCIENCE, INC.
    • BELLBROOK LABS
    • PROFACGEN
    • BMG LABTECH GMBH
    • HANUGEN THERAPEUTICS
    • ALTOGEN LABS
    • BIOAGILYTIX LABS

第13章 付録

図表

List of Tables

  • TABLE 1 CELL-BASED ASSAYS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 CELL-BASED ASSAYS MARKET: IMPACT ANALYSIS
  • TABLE 4 ESTIMATED EXPENDITURE BY US NIH FOR STEM CELL RESEARCH, 2019-2025
  • TABLE 5 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2022 VS. 2045
  • TABLE 6 CELL-BASED ASSAYS MARKET: KEY DEVELOPMENTS
  • TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021-2024
  • TABLE 8 AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024
  • TABLE 9 CELL-BASED ASSAYS MARKET: ROLE OF RAW MATERIAL VENDORS
  • TABLE 10 CELL-BASED ASSAYS MARKET: ROLE OF PRODUCT/SERVICE VENDORS
  • TABLE 11 CELL-BASED ASSAYS MARKET: ROLE OF END USERS
  • TABLE 12 CELL-BASED ASSAYS MARKET: ROLE OF REGULATORY BODIES
  • TABLE 13 NUMBER OF PATENTS APPLIED AND GRANTED, JANUARY 2014-APRIL 2025
  • TABLE 14 INNOVATIONS AND PATENT REGISTRATIONS, 2025
  • TABLE 15 CELL-BASED ASSAYS MARKET: LIST OF KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 16 AVERAGE TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS FOR HS CODE 9027, 2024
  • TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 CELL-BASED ASSAYS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 22 BUYING CRITERIA FOR CELL-BASED ASSAY PRODUCTS, BY END USER
  • TABLE 23 IMPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020-2024 (USD THOUSAND)
  • TABLE 24 IMPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020-2024 (TONS)
  • TABLE 25 EXPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020-2024 (USD THOUSAND)
  • TABLE 26 EXPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020-2024 (TONS)
  • TABLE 27 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 28 CELL-BASED ASSAY PRODUCTS-RELATED TARIFF REVISION
  • TABLE 29 IMPACT ON END-USE APPLICATIONS OF CELL-BASED ASSAY PRODUCTS
  • TABLE 30 CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 31 CONSUMABLES OFFERED BY KEY COMPANIES
  • TABLE 32 CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 33 CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 REAGENTS OFFERED BY KEY COMPANIES
  • TABLE 41 REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 EUROPE: REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 LATIN AMERICA: REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 MIDDLE EAST: REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 GCC COUNTRIES: REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 ASSAY KITS OFFERED BY KEY COMPANIES
  • TABLE 49 ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 50 ASSAY KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 NORTH AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 EUROPE: ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 LATIN AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 MIDDLE EAST: ASSAY KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 GCC COUNTRIES: ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 REPORTER GENE ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 EUROPE: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 CELL GROWTH ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 EUROPE: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 LATIN AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 MIDDLE EAST: CELL GROWTH ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 GCC COUNTRIES: CELL GROWTH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 SECONDARY MESSENGER ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 72 NORTH AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 EUROPE: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 LATIN AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 MIDDLE EAST: SECONDARY MESSENGER ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 GCC COUNTRIES: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 CELL DEATH ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 79 NORTH AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 EUROPE: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 MIDDLE EAST: CELL DEATH ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 GCC COUNTRIES: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 OTHER ASSAY KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 EUROPE: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 MIDDLE EAST: OTHER ASSAY KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 MICROPLATES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: MICROPLATES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 EUROPE: MICROPLATES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: MICROPLATES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 LATIN AMERICA: MICROPLATES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 MIDDLE EAST: MICROPLATES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: MICROPLATES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 100 CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 EUROPE: CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 MIDDLE EAST: CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 106 GCC COUNTRIES: CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 IMMORTALIZED CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 EUROPE: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 MIDDLE EAST: IMMORTALIZED CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 113 GCC COUNTRIES: IMMORTALIZED CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 PRIMARY CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 MIDDLE EAST: PRIMARY CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 120 GCC COUNTRIES: PRIMARY CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 STEM CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 122 NORTH AMERICA: STEM CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 EUROPE: STEM CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: STEM CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 LATIN AMERICA: STEM CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 MIDDLE EAST: STEM CELL LINES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 127 GCC COUNTRIES: STEM CELL LINES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 PROBES & LABELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 129 NORTH AMERICA: PROBES & LABELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 EUROPE: PROBES & LABELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: PROBES & LABELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 LATIN AMERICA: PROBES & LABELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 MIDDLE EAST: PROBES & LABELS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: PROBES & LABELS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 OTHER CONSUMABLES OFFERED BY KEY COMPANIES
  • TABLE 136 OTHER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 142 GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 EUROPE: INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 MIDDLE EAST: INSTRUMENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 149 GCC COUNTRIES: INSTRUMENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 151 NORTH AMERICA: SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 EUROPE: SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 MIDDLE EAST: SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 158 NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 159 EUROPE: SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 MIDDLE EAST: SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 165 CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 166 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 EUROPE: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 172 CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 173 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 EUROPE: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 176 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 177 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 178 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 179 CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 180 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 EUROPE: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 184 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 187 NORTH AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 188 EUROPE: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 190 LATIN AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 191 MIDDLE EAST: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 192 GCC COUNTRIES: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 193 CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 194 CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 195 CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 196 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 197 EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 199 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 200 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 201 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 203 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 204 EUROPE: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 206 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 207 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 208 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 209 CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 210 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 211 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 213 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 214 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 215 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 216 CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 217 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 218 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 220 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 221 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 222 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 223 CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 224 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 225 EUROPE: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 227 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 228 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 229 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 230 CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 231 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 232 EUROPE: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 234 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 235 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 236 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 237 CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 238 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 239 EUROPE: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 241 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 242 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 243 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 244 CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 245 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)
  • TABLE 246 CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 247 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 248 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 249 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 250 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 251 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 252 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 253 CELL-BASED ASSAYS MARKET FOR CROS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 254 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 255 EUROPE: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 257 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 258 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR CROS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 260 CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 261 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 262 EUROPE: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 263 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 264 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 265 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 266 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 267 CELL-BASED ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 268 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 269 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 270 NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 271 NORTH AMERICA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 272 NORTH AMERICA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 273 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 274 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 275 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 276 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 277 US: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 278 US: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 279 US: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 280 US: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 US: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 282 US: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 283 US: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 284 US: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 285 CANADA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 286 CANADA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 287 CANADA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 CANADA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 289 CANADA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 290 CANADA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 291 CANADA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 292 CANADA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 293 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 294 EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 295 EUROPE: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 296 EUROPE: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 297 EUROPE: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 298 EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 299 EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 300 EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 301 EUROPE: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 302 GERMANY: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 303 GERMANY: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 304 GERMANY: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 305 GERMANY: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 306 GERMANY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 307 GERMANY: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 308 GERMANY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 309 GERMANY: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 310 UK: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 311 UK: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 312 UK: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 313 UK: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 314 UK: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 315 UK: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 316 UK: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 317 UK: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 318 FRANCE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 319 FRANCE: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 FRANCE: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 321 FRANCE: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 322 FRANCE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 323 FRANCE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 324 FRANCE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 325 FRANCE: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 326 ITALY: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 327 ITALY: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 328 ITALY: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 329 ITALY: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 330 ITALY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 331 ITALY: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 332 ITALY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 333 ITALY: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 334 SPAIN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 335 SPAIN: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 336 SPAIN: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 337 SPAIN: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 338 SPAIN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 339 SPAIN: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 340 SPAIN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 341 SPAIN: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 342 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 343 REST OF EUROPE: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 344 REST OF EUROPE: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 345 REST OF EUROPE: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 346 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 347 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 348 REST OF EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 349 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 350 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 351 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 352 ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 353 ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 354 ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 355 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 356 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 357 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 358 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 359 CHINA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 360 CHINA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 361 CHINA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 362 CHINA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 363 CHINA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 364 CHINA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 365 CHINA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 366 CHINA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 367 JAPAN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 368 JAPAN: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 369 JAPAN: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 370 JAPAN: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 371 JAPAN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 372 JAPAN: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 373 JAPAN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 374 JAPAN: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 375 INDIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 376 INDIA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 377 INDIA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 378 INDIA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 379 INDIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 380 INDIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 381 INDIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 INDIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 383 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 384 AUSTRALIA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 385 AUSTRALIA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 386 AUSTRALIA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 387 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 388 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 389 AUSTRALIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 390 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 391 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 392 SOUTH KOREA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 393 SOUTH KOREA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 394 SOUTH KOREA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 395 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 396 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 397 SOUTH KOREA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 398 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 399 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 400 REST OF ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 401 REST OF ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 402 REST OF ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 403 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 404 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 405 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 406 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 407 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 408 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 409 LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 410 LATIN AMERICA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 411 LATIN AMERICA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 412 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 413 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 414 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 415 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 416 BRAZIL: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 417 BRAZIL: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 418 BRAZIL: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 419 BRAZIL: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 420 BRAZIL: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 421 BRAZIL: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 422 BRAZIL: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 423 BRAZIL: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 424 MEXICO: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 425 MEXICO: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 426 MEXICO: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 427 MEXICO: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 428 MEXICO: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 429 MEXICO: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 430 MEXICO: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 431 MEXICO: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 432 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 433 REST OF LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 434 REST OF LATIN AMERICA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 435 REST OF LATIN AMERICA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 436 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 437 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 438 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 439 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 440 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 441 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 442 MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 443 MIDDLE EAST: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 444 MIDDLE EAST: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 445 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 446 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 447 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 448 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 449 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 450 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 451 GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 452 GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 453 GCC COUNTRIES: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 454 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 455 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 456 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 457 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 458 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 459 SAUDI ARABIA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 460 SAUDI ARABIA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 461 SAUDI ARABIA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 462 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 463 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 464 SAUDI ARABIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 465 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 466 UAE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 467 UAE: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 468 UAE: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 469 UAE: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 470 UAE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 471 UAE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 472 UAE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 473 UAE: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 474 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 475 REST OF GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 476 REST OF GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 477 REST OF GCC COUNTRIES: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 478 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 479 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 480 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 481 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 482 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 483 REST OF MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 484 REST OF MIDDLE EAST: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 485 REST OF MIDDLE EAST: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 486 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 487 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 488 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 489 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 490 AFRICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 491 AFRICA: CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 492 AFRICA: ASSAY KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 493 AFRICA: CELL LINES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 494 AFRICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 495 AFRICA: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 496 AFRICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 497 AFRICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 498 OVERVIEW OF STRATEGIES DEPLOYED BY MANUFACTURING COMPANIES, JANUARY 2021-APRIL 2025
  • TABLE 499 CELL-BASED ASSAYS MARKET: DEGREE OF COMPETITION
  • TABLE 500 CELL-BASED ASSAYS MARKET: OFFERING FOOTPRINT
  • TABLE 501 CELL-BASED ASSAYS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 502 CELL-BASED ASSAYS MARKET: APPLICATION FOOTPRINT
  • TABLE 503 CELL-BASED ASSAYS MARKET: REGION FOOTPRINT
  • TABLE 504 CELL-BASED ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 505 CELL-BASED ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 506 CELL-BASED ASSAYS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 507 CELL-BASED ASSAYS MARKET: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 508 CELL-BASED ASSAYS MARKET: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 509 DANAHER: COMPANY OVERVIEW
  • TABLE 510 DANAHER: PRODUCTS/SERVICES OFFERED
  • TABLE 511 DANAHER: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 512 DANAHER: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 513 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 514 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 515 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 516 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 517 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 518 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 519 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 520 MERCK KGAA: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 521 MERCK KGAA: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 522 BD: BUSINESS OVERVIEW
  • TABLE 523 BD: PRODUCTS/SERVICES OFFERED
  • TABLE 524 BD: PRODUCT LAUNCHES, JANUARY 2021-APRIL 2025
  • TABLE 525 BD: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 526 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 527 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 528 AGILENT TECHNOLOGIES, INC.: PRODUCTS LAUNCHES, JANUARY 2021-APRIL 2025
  • TABLE 529 LONZA: COMPANY OVERVIEW
  • TABLE 530 LONZA: PRODUCTS/SERVICES OFFERED
  • TABLE 531 LONZA: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 532 LONZA: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 533 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 534 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
  • TABLE 535 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 536 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 537 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
  • TABLE 538 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES, JANUARY 2021-APRIL 2025
  • TABLE 539 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 540 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 541 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 542 REVVITY: COMPANY OVERVIEW
  • TABLE 543 REVVITY: PRODUCTS/SERVICES OFFERED
  • TABLE 544 REVVITY: PRODUCT LAUNCHES, JANUARY 2021-APRIL 2025
  • TABLE 545 SARTORIUS AG: COMPANY OVERVIEW
  • TABLE 546 SARTORIUS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 547 SARTORIUS AG: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 548 CORNING INCORPORATED: COMPANY OVERVIEW
  • TABLE 549 CORNING INCORPORATED: PRODUCTS/SERVICES OFFERED
  • TABLE 550 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 551 PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 552 PROMEGA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-APRIL 2025
  • TABLE 553 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 554 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 555 ENZO BIOCHEM INC.: COMPANY OVERVIEW
  • TABLE 556 ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 557 ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 558 CARNA BIOSCIENCES, INC.: BUSINESS OVERVIEW
  • TABLE 559 CARNA BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 560 INTERTEK GROUP PLC: COMPANY OVERVIEW
  • TABLE 561 INTERTEK GROUP PLC: PRODUCTS /SERVICES OFFERED
  • TABLE 562 INTERTEK GROUP PLC: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 563 BICO: COMPANY OVERVIEW
  • TABLE 564 BICO: PRODUCTS/SERVICES OFFERED

List of Figures

  • FIGURE 1 CELL-BASED ASSAYS MARKET: SEGMENTS & REGIONS CONSIDERED
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARIES: CELL-BASED ASSAYS MARKET
  • FIGURE 4 CELL-BASED ASSAYS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH), 2024
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 CELL-BASED ASSAYS MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 CELL-BASED ASSAYS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 CELL-BASED ASSAYS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 CELL-BASED ASSAYS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CELL-BASED ASSAYS MARKET
  • FIGURE 16 GROWING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET
  • FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024
  • FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT HELD MAJOR MARKET SHARE IN 2024
  • FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 21 CELL-BASED ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 AGE-STANDARDIZED RATE (WORLD) PER 100,000 CANCER INCIDENCES IN BOTH SEXES, 2022
  • FIGURE 23 CELL-BASED ASSAYS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 PRICING ANALYSIS FOR CELL-BASED ASSAY PRODUCTS, 2022-2024
  • FIGURE 25 CELL-BASED ASSAYS MARKET ECOSYSTEM
  • FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 27 PATENT APPLICATION IN CELL-BASED ASSAYS MARKET, JANUARY 2014-APRIL 2025
  • FIGURE 28 CELL-BASED ASSAYS MARKET: PORTER'S FIVE ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL-BASED ASSAY PRODUCTS
  • FIGURE 30 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 31 CELL-BASED ASSAYS MARKET: INVESTMENT AND FUNDING SCENARIO, 2020-2024
  • FIGURE 32 IMPACT OF AI/GEN AI ON CELL-BASED ASSAYS MARKET
  • FIGURE 33 INSTRUMENTS MARKET (FLOW CYTOMETERS) FOR CELL-BASED ASSAYS, 2023-2030 (THOUSAND UNITS)
  • FIGURE 34 WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2021-2028
  • FIGURE 35 NORTH AMERICA: CELL-BASED ASSAYS MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: CELL-BASED ASSAYS MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN CELL-BASED ASSAYS MARKET (2020-2024)
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL-BASED ASSAYS MARKET (2024)
  • FIGURE 39 CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 40 CELL-BASED ASSAYS MARKET: COMPANY FOOTPRINT
  • FIGURE 41 CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX, (STARTUPS/SMES), 2024
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 44 CELL-BASED ASSAYS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 DANAHER: COMPANY SNAPSHOT (2024)
  • FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 48 BD: COMPANY SNAPSHOT (2024)
  • FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 LONZA: COMPANY SNAPSHOT (2024)
  • FIGURE 51 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
  • FIGURE 52 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 REVVITY: COMPANY SNAPSHOT (2024)
  • FIGURE 55 SARTORIUS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 56 CORNING INCORPORATED: COMPANY SNAPSHOT (2024)
  • FIGURE 57 ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 CARNA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 59 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 60 BICO: COMPANY SNAPSHOT (2024)
目次
Product Code: BT 2486

The cell-based assays market is projected to reach USD 27.55 billion by 2030 from an estimated USD 17.84 billion in 2025, at a CAGR of 9.1% during the forecast period from 2025 to 2030. This growth can be largely attributed to the increasing demand for drug discovery and the rising need for cell-based assays in this area. Furthermore, higher research & development investments from the pharmaceutical and biotechnology industries are driving the growth of the cell-based assays market. Additionally, the growing incidence of cancer is increasing the demand for advanced therapies, which further boosts market expansion. The expanding applications of cell-based assays in chronic diseases and personalized medicine are also expected to propel market growth in the coming years.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsOffering, Technology, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

"The drug discovery segment accounted for the largest share of the application segment in 2024."

The cell-based assays market is segmented by application into drug discovery, basic research, genetic studies, and other applications. The drug discovery segment is further categorized into toxicity, pharmacokinetic, and pharmacodynamic studies. In 2024, the drug discovery segment accounted for the largest share of the global cell-based assays market. The increasing prevalence of cancer is driving the demand for advanced therapies, which, in turn, promotes the growth of this segment within the cell-based assays market. Additionally, rising investments in research and development, the introduction of new drugs, and a growing number of contract research organizations offering drug discovery services to pharmaceutical and biotechnology companies are also expected to contribute to the segment's continued growth in the cell-based assays market.

"The flow cytometry segment accounted for a major share of the technology market in 2024."

The cell-based assays market is categorized by technology into flow cytometry, high-throughput screening, label-free detection, and other technologies. In 2024, flow cytometry held the largest share of the global cell-based assays market within this category. The growth of the flow cytometry segment is primarily due to its widespread use in cell-based assays, allowing for multiple measurements. Additionally, the increasing adoption of advanced technologies for cell analysis and characterization is expected to further enhance the growth of this segment in the cell-based assays market.

"The US dominated the cell-based assays market in 2024."

The cell-based assays market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, the US dominated the cell-based assays market in North America. As the largest biopharmaceutical market in the world, the US leads in biopharmaceutical research and investments. The country also boasts a robust healthcare infrastructure that supports research and development in the life sciences sector.

Additionally, the significant presence of numerous biopharmaceutical companies and increased research activities in the biotechnology industry are driving market growth in the US. Furthermore, the rising emphasis on developing advanced cell-based therapies, prompted by the increasing incidence of cancer, contributes to the growth of the cell-based assays market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side (60%) and Demand Side (40%)
  • By Designation: Managers (45%), CXOs & Directors (30%0, and Executives (25%)
  • By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report:

  • BD (US)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • Merck KGaA (Germany)
  • Agilent Technologies, Inc. (US)
  • Lonza (Switzerland)
  • Charles River Laboratories (US)
  • Bio-Rad Laboratories, Inc. (US)
  • REVVITY (US)
  • Sartorius AG (Germany)
  • Corning Incorporated (US)
  • Promega Corporation (US)
  • Cell Signaling Technology, Inc. (US)
  • Eurofins Scientific (Luxembourg)
  • Enzo Biochem, Inc. (US)
  • Carna Biosciences, Inc. (Japan)
  • Intertek Group Plc (UK)
  • BICO (Sweden)
  • Cell Biolabs, Inc. (US)
  • Reaction Biology (US)
  • AAT Bioquest, Inc. (US)
  • Pestka Biomedical Laboratories, Inc. (US)
  • Neuromics (US)
  • BPS Bioscience, Inc. (US)
  • BellBrook Labs (US)
  • Profacgen (US)
  • BMG LABTECH (Germany)
  • Hanugen Therapeutics (India)
  • Altogen Labs (US)
  • BioAgilytix (US)

Research Coverage:

This research report categorizes the cell-based assays market by offering {consumables [reagents, assay kits (reporter gene assays, cell growth assays, secondary messenger assays, cell death assays, and other assay kits), microplates, cell lines (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables], instruments, software, and services}, technology (flow cytometry, high-throughput screening, label-free detection, and other technologies), application [drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications], end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This analysis also includes information about new product launches, collaborations, acquisitions, and recent developments related to the cell-based assays market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, a surge in cases of cancer, and increasing R&D investments and funding for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market.
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market.
  • Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), REVVITY (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group Plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), Altogen Labs (US), and BioAgilytix (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 INCLUSIONS & EXCLUSIONS
    • 1.3.2 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH)
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CELL-BASED ASSAYS MARKET
  • 4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2024)
  • 4.3 CELL-BASED ASSAYS MARKET, BY OFFERING, 2024
  • 4.4 CELL-BASED ASSAYS MARKET, BY END USER, 2024
  • 4.5 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery
      • 5.2.1.2 Government support and funding for cell-based research
      • 5.2.1.3 Growing efforts to curtail animal-based studies
      • 5.2.1.4 Rising prevalence of cancer
      • 5.2.1.5 Alliances to accelerate innovations in drug discovery
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of instruments and restrictions imposed by product end-user licenses for reagents
      • 5.2.2.2 Lack of standardization of protocols used in cell-based assays
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing applications of cell-based assays in chronic diseases and personalized medicine
      • 5.2.3.2 Growth opportunities in emerging economies
      • 5.2.3.3 Rising adoption of AI in drug discovery and cell analysis
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexities in assay designs
      • 5.2.4.2 Shortage of skilled professionals
  • 5.3 TECHNOLOGY ANALYSIS
    • 5.3.1 KEY TECHNOLOGIES
      • 5.3.1.1 Flow cytometry
      • 5.3.1.2 High-throughput screening
      • 5.3.1.3 High-content screening
      • 5.3.1.4 Label-free detection
    • 5.3.2 COMPLEMENTARY TECHNOLOGIES
      • 5.3.2.1 Artificial intelligence and machine learning
    • 5.3.3 ADJACENT TECHNOLOGIES
      • 5.3.3.1 Nanotechnology
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021-2024
    • 5.5.2 AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024
  • 5.6 ECOSYSTEM ANALYSIS
    • 5.6.1 RAW MATERIAL VENDORS
    • 5.6.2 PRODUCT/SERVICE VENDORS
    • 5.6.3 END USERS
    • 5.6.4 REGULATORY BODIES
  • 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE, 2014-2025
  • 5.9 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.10 TARIFF AND REGULATORY LANDSCAPE
    • 5.10.1 TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.3 REGULATORY FRAMEWORK
      • 5.10.3.1 North America
      • 5.10.3.2 Europe
      • 5.10.3.3 Asia Pacific
      • 5.10.3.4 Rest of the World
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 BUYING CRITERIA
  • 5.13 INVESTMENT AND FUNDING SCENARIO
  • 5.14 TRADE ANALYSIS
    • 5.14.1 IMPORT DATA
    • 5.14.2 EXPORT DATA
  • 5.15 IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET
  • 5.16 IMPACT OF 2025 US TARIFF ON CELL-BASED ASSAYS MARKET
    • 5.16.1 INTRODUCTION
    • 5.16.2 KEY TARIFF RATES
    • 5.16.3 PRICE IMPACT ANALYSIS
    • 5.16.4 IMPACT ON COUNTRY/REGION
      • 5.16.4.1 US
      • 5.16.4.2 Europe
      • 5.16.4.3 Asia Pacific
    • 5.16.5 IMPACT ON END-USE INDUSTRIES
      • 5.16.5.1 Pharmaceutical & biotech companies
      • 5.16.5.2 Contract research organizations (CROs)
      • 5.16.5.3 Academic & research institutes

6 CELL-BASED ASSAYS MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    • 6.2.1 REAGENTS
      • 6.2.1.1 High demand for reagents in research applications to propel market growth
    • 6.2.2 ASSAY KITS
      • 6.2.2.1 Reporter gene assays
        • 6.2.2.1.1 Versatility of reporter gene assays and widespread applications to fuel growth
      • 6.2.2.2 Cell growth assays
        • 6.2.2.2.1 Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market
      • 6.2.2.3 Secondary messenger assays
        • 6.2.2.3.1 Adoption of secondary messenger assays for cell signaling studies to fuel growth
      • 6.2.2.4 Cell death assays
        • 6.2.2.4.1 Importance of cell death quantification in drug development to favor growth
      • 6.2.2.5 Other assay kits
    • 6.2.3 MICROPLATES
      • 6.2.3.1 Demand for microplates in assay development to drive market
    • 6.2.4 CELL LINES
      • 6.2.4.1 Immortalized cell lines
        • 6.2.4.1.1 Wide use of immortalized cell lines to boost market
      • 6.2.4.2 Primary cell lines
        • 6.2.4.2.1 Advantages in drug development, preclinical research, and other applications to propel market
      • 6.2.4.3 Stem cell lines
        • 6.2.4.3.1 Rising use in tissue and disease models to fuel adoption
    • 6.2.5 PROBES & LABELS
      • 6.2.5.1 Growing need for effective cell labeling to boost demand
    • 6.2.6 OTHER CONSUMABLES
  • 6.3 INSTRUMENTS
    • 6.3.1 AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH
  • 6.4 SERVICES
    • 6.4.1 GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH
  • 6.5 SOFTWARE
    • 6.5.1 INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS TO DRIVE GROWTH

7 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 FLOW CYTOMETRY
    • 7.2.1 WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO DRIVE MARKET
  • 7.3 HIGH-THROUGHPUT SCREENING
    • 7.3.1 INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
  • 7.4 LABEL-FREE DETECTION
    • 7.4.1 GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND
  • 7.5 OTHER TECHNOLOGIES

8 CELL-BASED ASSAYS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 DRUG DISCOVERY
    • 8.2.1 TOXICITY STUDIES
      • 8.2.1.1 Increasing demand for cell-based assays in toxicity testing to fuel growth
    • 8.2.2 PHARMACOKINETIC STUDIES
      • 8.2.2.1 Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays
    • 8.2.3 PHARMACODYNAMIC STUDIES
      • 8.2.3.1 Advantages of cell-based assays in pharmacodynamics to propel growth
  • 8.3 BASIC RESEARCH
    • 8.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES
  • 8.4 GENETIC STUDIES
    • 8.4.1 INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET
  • 8.5 OTHER APPLICATIONS

9 CELL-BASED ASSAYS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 GROWTH IN R&D EFFORTS TOWARD CELL-BASED ASSAYS IN PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTORS TO DRIVE MARKET
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE MARKET

10 CELL-BASED ASSAYS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK
    • 10.2.2 US
      • 10.2.2.1 Established pharmaceutical and biotechnology sectors to drive market
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing funding and investments to drive market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK
    • 10.3.2 GERMANY
      • 10.3.2.1 To dominate cell-based assays market in Europe
    • 10.3.3 UK
      • 10.3.3.1 Growing cancer research funding to increase demand for cell-based assays
    • 10.3.4 FRANCE
      • 10.3.4.1 Growing biotechnology sector to drive market
    • 10.3.5 ITALY
      • 10.3.5.1 Growth of pharmaceutical industry to boost market
    • 10.3.6 SPAIN
      • 10.3.6.1 Rising research activity and increasing number of biotech companies to favor market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing R&D expenditure to favor market growth
    • 10.4.3 JAPAN
      • 10.4.3.1 Government initiatives for drug innovation to support market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing investments in R&D and funding for life science research to propel market
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Booming life science sector to propel market
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Increasing strategic alliances to support market growth
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK
    • 10.5.2 BRAZIL
      • 10.5.2.1 Brazil to hold largest share of Latin American market
    • 10.5.3 MEXICO
      • 10.5.3.1 Government support for biopharmaceutical production to support market growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST
    • 10.6.1 MACROECONOMIC OUTLOOK
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 Saudi Arabia
        • 10.6.2.1.1 Increasing R&D investments to drive market
      • 10.6.2.2 UAE
        • 10.6.2.2.1 Investments and support for biopharma sector to offer growth opportunities
      • 10.6.2.3 Rest of GCC Countries
    • 10.6.3 REST OF MIDDLE EAST
  • 10.7 AFRICA
    • 10.7.1 RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
    • 10.7.2 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL-BASED ASSAYS MARKET
  • 11.3 REVENUE ANALYSIS, 2020-2024
  • 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Offering footprint
      • 11.5.5.3 Technology footprint
      • 11.5.5.4 Application Footprint
      • 11.5.5.5 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 11.6.5.1 Detailed list of key startups/SMEs
      • 11.6.5.2 Competitive benchmarking of key emerging players/startups
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 11.9.2 DEALS
    • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYERS
    • 12.2.1 DANAHER
      • 12.2.1.1 Business overview
      • 12.2.1.2 Products/Services offered
      • 12.2.1.3 Recent developments
        • 12.2.1.3.1 Deals
        • 12.2.1.3.2 Expansions
      • 12.2.1.4 MnM view
        • 12.2.1.4.1 Key strengths
        • 12.2.1.4.2 Strategic choices
        • 12.2.1.4.3 Weaknesses & competitive threats
    • 12.2.2 THERMO FISHER SCIENTIFIC INC.
      • 12.2.2.1 Business overview
      • 12.2.2.2 Products/Services offered
      • 12.2.2.3 Recent developments
        • 12.2.2.3.1 Deals
        • 12.2.2.3.2 Expansions
        • 12.2.2.3.3 Other developments
      • 12.2.2.4 MnM view
        • 12.2.2.4.1 Key strengths
        • 12.2.2.4.2 Strategic choices
        • 12.2.2.4.3 Weaknesses & competitive threats
    • 12.2.3 MERCK KGAA
      • 12.2.3.1 Business overview
      • 12.2.3.2 Products/Services offered
      • 12.2.3.3 Recent developments
        • 12.2.3.3.1 Deals
        • 12.2.3.3.2 Expansions
      • 12.2.3.4 MnM view
        • 12.2.3.4.1 Key strengths
        • 12.2.3.4.2 Strategic choices
        • 12.2.3.4.3 Weaknesses & competitive threats
    • 12.2.4 BD
      • 12.2.4.1 Business overview
      • 12.2.4.2 Products/Services offered
      • 12.2.4.3 Recent developments
        • 12.2.4.3.1 Product launches
        • 12.2.4.3.2 Deals
      • 12.2.4.4 MnM view
        • 12.2.4.4.1 Key strengths
        • 12.2.4.4.2 Strategic choices
        • 12.2.4.4.3 Weaknesses & competitive threats
    • 12.2.5 AGILENT TECHNOLOGIES, INC.
      • 12.2.5.1 Business overview
      • 12.2.5.2 Products/Services offered
      • 12.2.5.3 Recent developments
        • 12.2.5.3.1 Product launches
      • 12.2.5.4 MnM view
        • 12.2.5.4.1 Key strengths
        • 12.2.5.4.2 Strategic choices
        • 12.2.5.4.3 Weaknesses & competitive threats
    • 12.2.6 LONZA
      • 12.2.6.1 Business overview
      • 12.2.6.2 Products/Services offered
      • 12.2.6.3 Recent developments
        • 12.2.6.3.1 Deals
        • 12.2.6.3.2 Expansions
    • 12.2.7 EUROFINS SCIENTIFIC
      • 12.2.7.1 Business overview
      • 12.2.7.2 Products/Services offered
      • 12.2.7.3 Recent developments
        • 12.2.7.3.1 Deals
    • 12.2.8 CHARLES RIVER LABORATORIES
      • 12.2.8.1 Business overview
      • 12.2.8.2 Products/services offered
      • 12.2.8.3 Recent developments
        • 12.2.8.3.1 Service launches
        • 12.2.8.3.2 Deals
    • 12.2.9 BIO-RAD LABORATORIES, INC.
      • 12.2.9.1 Business overview
      • 12.2.9.2 Products/Services offered
    • 12.2.10 REVVITY
      • 12.2.10.1 Business overview
      • 12.2.10.2 Products/Services offered
      • 12.2.10.3 Recent developments
        • 12.2.10.3.1 Product launches
    • 12.2.11 SARTORIUS AG
      • 12.2.11.1 Business overview
      • 12.2.11.2 Products/Services offered
      • 12.2.11.3 Recent developments
        • 12.2.11.3.1 Expansions
    • 12.2.12 CORNING INCORPORATED
      • 12.2.12.1 Business overview
      • 12.2.12.2 Products/Services offered
    • 12.2.13 PROMEGA CORPORATION
      • 12.2.13.1 Business overview
      • 12.2.13.2 Products/Services offered
      • 12.2.13.3 Recent developments
        • 12.2.13.3.1 Product launches
    • 12.2.14 CELL SIGNALING TECHNOLOGY, INC.
      • 12.2.14.1 Business overview
      • 12.2.14.2 Products/Services offered
    • 12.2.15 ENZO BIOCHEM INC.
      • 12.2.15.1 Business overview
      • 12.2.15.2 Products/Services offered
      • 12.2.15.3 Recent developments
        • 12.2.15.3.1 Expansions
    • 12.2.16 CARNA BIOSCIENCES, INC.
      • 12.2.16.1 Business overview
      • 12.2.16.2 Products/Services offered
    • 12.2.17 INTERTEK GROUP PLC
      • 12.2.17.1 Business overview
      • 12.2.17.2 Products/services offered
      • 12.2.17.3 Recent developments
        • 12.2.17.3.1 Expansions
    • 12.2.18 BICO
      • 12.2.18.1 Business overview
      • 12.2.18.2 Products/Services offered
  • 12.3 OTHER PLAYERS
    • 12.3.1 CELL BIOLABS, INC.
    • 12.3.2 REACTION BIOLOGY
    • 12.3.3 AAT BIOQUEST, INC.
    • 12.3.4 PESTKA BIOMEDICAL LABORATORIES, INC.
    • 12.3.5 NEUROMICS
    • 12.3.6 BPS BIOSCIENCE, INC.
    • 12.3.7 BELLBROOK LABS
    • 12.3.8 PROFACGEN
    • 12.3.9 BMG LABTECH GMBH
    • 12.3.10 HANUGEN THERAPEUTICS
    • 12.3.11 ALTOGEN LABS
    • 12.3.12 BIOAGILYTIX LABS

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS